Geode Capital Management LLC Sells 2,338 Shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR)

Geode Capital Management LLC cut its position in shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR) by 0.9% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 257,416 shares of the company’s stock after selling 2,338 shares during the quarter. Geode Capital Management LLC’s holdings in Jasper Therapeutics were worth $4,843,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Bank of New York Mellon Corp acquired a new stake in shares of Jasper Therapeutics during the 2nd quarter worth approximately $740,000. Rhumbline Advisers bought a new position in Jasper Therapeutics in the second quarter worth $300,000. American Century Companies Inc. boosted its stake in Jasper Therapeutics by 27.1% during the second quarter. American Century Companies Inc. now owns 14,204 shares of the company’s stock worth $322,000 after buying an additional 3,032 shares in the last quarter. Wolff Wiese Magana LLC bought a new stake in Jasper Therapeutics in the 3rd quarter valued at $59,000. Finally, Fernwood Investment Management LLC raised its stake in shares of Jasper Therapeutics by 6.9% in the 3rd quarter. Fernwood Investment Management LLC now owns 52,897 shares of the company’s stock valued at $995,000 after buying an additional 3,427 shares in the last quarter. 79.85% of the stock is owned by institutional investors and hedge funds.

Jasper Therapeutics Stock Down 8.6 %

Shares of NASDAQ JSPR opened at $19.27 on Friday. Jasper Therapeutics, Inc. has a 12-month low of $6.50 and a 12-month high of $31.01. The firm’s 50-day simple moving average is $22.07 and its 200 day simple moving average is $20.52. The company has a market cap of $289.07 million, a price-to-earnings ratio of -4.07 and a beta of 2.18.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on JSPR shares. Royal Bank of Canada reissued an “outperform” rating and issued a $68.00 target price on shares of Jasper Therapeutics in a research note on Monday, December 23rd. HC Wainwright reissued a “buy” rating and issued a $65.00 target price on shares of Jasper Therapeutics in a report on Thursday, October 24th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Jasper Therapeutics in a research note on Monday, September 9th. JMP Securities reiterated a “market outperform” rating and set a $70.00 price objective on shares of Jasper Therapeutics in a research note on Tuesday, October 15th. Finally, BMO Capital Markets initiated coverage on shares of Jasper Therapeutics in a research note on Friday, December 6th. They issued an “outperform” rating and a $63.00 target price on the stock. Ten investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $73.38.

About Jasper Therapeutics

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.